This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / Lobbying Aids Grand Pharma Against FastWave
Regulatory lobbying dispute

Lobbying Aids Grand Pharma Against FastWave

Analysis based on 6 articles · First reported Apr 09, 2026 · Last updated Apr 10, 2026

Sentiment
-20
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The event highlights the influence of lobbying on U.S. national security reviews, potentially impacting investor confidence in the fairness of such processes. The near-bankruptcy of FastWave due to the CFIUS decision could deter startups from seeking foreign investment if they perceive a lack of protection against intellectual property concerns.

Biotechnology Lobbying Government
Event Summary

A lobbying firm, Checkmate, with ties to Donald Trump, helped Grand Pharmaceutical Group, a Chinese company, secure a meeting with the head of the United States — Committee on Foreign Investment in the United States (CFIUS). This meeting preceded CFIUS's decision to reject a filing by U.S. startup FastWave, which sought to force Grand Pharmaceutical Group to divest its 40% stake due to concerns about intellectual property theft and blocking fundraising. CFIUS cited 'material misstatements' by FastWave for the rejection, not national security risks. This outcome has brought FastWave to the brink of bankruptcy and raised concerns among lawmakers and experts about Chinese companies gaining influence over the U.S. administration through lobbying.

Entities Involved
stock
Grand Pharmaceutical Group
Grand Pharmaceutical Group, a Chinese company, achieved a rare win in Washington as CFIUS rejected FastWave's request for a national security review of its investment. This allows Grand Pharmaceutical Group to maintain its 40% stake in FastWave.
Importance 90.0 Sentiment 30.0
priv
Checkmate
Checkmate, a lobbying firm, successfully helped Grand Pharmaceutical Group secure a meeting with CFIUS leadership, leading to a favorable outcome for Grand Pharmaceutical Group against FastWave. This highlights the firm's influence through its connections.
Importance 80.0 Sentiment 20.0
govactor
United States — Committee on Foreign Investment in the United States
CFIUS rejected FastWave's filing, effectively siding with Grand Pharmaceutical Group, citing 'material misstatements' by FastWave. This decision has raised concerns about the committee's process and potential influence from lobbyists.
Importance 70.0 Sentiment -10.0
per
Ches McDowell
Ches McDowell, a leader of Checkmate and a hunting buddy of Donald Trump, is central to the lobbying effort that secured a meeting for Grand Pharmaceutical Group with CFIUS leadership. His connections are highlighted as a key factor in Checkmate's success.
Importance 60.0 Sentiment 10.0
per
Scott Nelson
Scott Nelson, CEO of FastWave, expressed concerns about the 'opaque and highly irregular procedural decisions' by CFIUS, which have made it difficult for his company to protect its technology and led to its financial distress.
Importance 60.0 Sentiment -70.0
per
Chris Pilkerton
Chris Pilkerton, as the head of CFIUS, met with Grand Pharmaceutical Group's lawyer, Jeff Bialos, a meeting arranged by Checkmate. The decision to reject FastWave's filing was made under his leadership.
Importance 50.0 Sentiment -10.0
per
Jeff Bialos
Jeff Bialos, Grand Pharmaceutical Group's lawyer, successfully argued the case to CFIUS, asserting it was a commercial dispute without national security implications, leading to a favorable outcome for his client.
Importance 50.0 Sentiment 10.0
cnt
United States
The United States' national security review process, specifically through CFIUS, is under scrutiny due to the outcome of this case, raising questions about the integrity of its decisions and the influence of lobbying.
Importance 50.0 Sentiment -10.0
per
Donald Trump
Donald Trump's association with Ches McDowell, a leader of Checkmate, has raised concerns among some lawmakers about potential influence peddling by Chinese companies on the Trump administration, though there is no indication of his direct involvement.
Importance 40.0 Sentiment 0.0
cnt
China
China, through Grand Pharmaceutical Group, achieved a rare win in a U.S. national security review, which could be seen as a positive for Chinese companies seeking to invest in the U.S.
Importance 40.0 Sentiment 10.0
priv
Jiangsu Zhenyi Medical Technology
Jiangsu Zhenyi Medical Technology is a Chinese rival to FastWave, and Grand Pharmaceutical Group's partnership with it raised FastWave's concerns about intellectual property theft.
Importance 20.0 Sentiment 0.0
Relationships
United States related ↔ Donald Trump
United States rivals ↔ China The United States treats China as a major economic and geopolitical adversary, aggressively imposing sweeping tariffs an
Donald Trump trade adversary ↔ China As President of the United States, Donald Trump has initiated an escalating trade war against China by imposing sweeping
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.